(1) The three months ended March 31, 2025 and 2026 includes the acceleration of stock compensation expense associated with employees reaching eligible retirement age. (2) The three months ended March ...

(2) Includes the write-down of leasehold improvements, right of use assets and/or other assets and exit costs associated with consolidation of certain facilities. (3) Includes gain on insurance ...

CLB faces persistent geopolitical uncertainty, weaker laboratory activity, cost inflation and delayed shipments, limiting ...

of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards. (2) Three months ended March 31, 2023 includes the ...

REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR OPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEAR GAAP LOSS PER SHARE OF ...

(1) Three months ended June 30, 2023 include reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards.

Good day, and welcome to the Core Laboratories third-quarter 2023 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

FIRST QUARTER 2026 EARNINGS WEBCAST AT 7:30 A.M. CDT / 8:30 A.M. EDT ON APRIL 30, 2026 HOUSTON, March 23, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company ...